Race, Ethnicity, and Diffuse Parenchymal Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00453713
Recruitment Status : Completed
First Posted : March 29, 2007
Last Update Posted : April 21, 2015
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
David J. Lederer, M.D., Columbia University

Brief Summary:
The purpose of this study is to identify factors that contribute to higher mortality rates among blacks and Hispanics with diffuse parenchymal lung disease.

Condition or disease
Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Diffuse Parenchymal Lung Disease

Detailed Description:
It is well known that both socioeconomic and biological factors may contribute to race- and ethnicity-based health disparities. Black and Hispanic Americans have worse access to healthcare services and tend to receive care from physicians who cannot themselves access the same services for their patients that physicians who care for white patients can. These factors may play important roles in the development and maintenance of health disparities. In addition, biological differences may contribute to disparities. We propose to identify factors that explain survival disparities in a group of lung diseases called diffuse parenchymal lung diseases (DPLDs), including a severe form of DPLD called idiopathic pulmonary fibrosis (IPF). We will follow patients with DPLD at our center and measure both social and biological factors to try to identify the factors that lead to survival disparities between races. Results of this study will be used to design clinical trials aimed at reducing these disparities.

Study Type : Observational
Actual Enrollment : 565 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Determinants of Outcome in Diffuse Parenchymal Lung Disease
Study Start Date : July 2006
Actual Primary Completion Date : August 2013
Actual Study Completion Date : August 2013

Biospecimen Retention:   Samples With DNA
Plasma/serum, DNA, and circulating cells and endothelial microparticles will be collected and processed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diffuse parenchymal lung disease

Inclusion Criteria:

  • Diagnosis of IPF or other DPLD according to ATS criteria
  • Signed informed consent

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00453713

United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Columbia University
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: David J Lederer, M.D. Columbia University

Responsible Party: David J. Lederer, M.D., Irving Assistant Professor of Medicine (in Pediatrics), Columbia University Identifier: NCT00453713     History of Changes
Other Study ID Numbers: AAAB8771
K23HL086714 ( U.S. NIH Grant/Contract )
First Posted: March 29, 2007    Key Record Dates
Last Update Posted: April 21, 2015
Last Verified: April 2015

Keywords provided by David J. Lederer, M.D., Columbia University:
Idiopathic pulmonary fibrosis
Interstitial lung disease
Diffuse parenchymal lung disease
Health disparities

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases